



enablecares

Entrepreneurship Course

ONLINE CLOSURE EVENT

09 MARCH 2023

10:00-10:15 Welcome

10:15-11:15 Business case workshop by Jeff Skinner

Teaching Fellow of Strategy & Entrepreneurship at London Business School

11:15-11:20 Screen Break

11:20-12:25 Round-table

Elisa Gambini, PhD, Chief Technology & Operating Officer at Oloker Therapeutics

Valerie Vanhooren, PhD, Chief Executive Officer at Ona Therapeutics

Thomas van den Heuvel, PhD, Chief Executive Officer at Ardim

Moderator: Pier Giorgio Mastroberardino, PhD, MBA

Principal Investigator at IFOM & Erasmus Medical Center


12:25-12:30 Closure

Enablecares Entrepreneurship Course, a high-level training activity optimised for the biomedical field, has been empowering junior scientists by giving them the necessary tools to explore their potential skills as an entrepreneur and their interest in undertaking a career in business or innovation management.

In this “Online Closure Event”, participants from previous editions of the course from Barcelona, Nijmegen, Milan & Copenhagen are invited to come together to enhance the multi-site experience & put into practice the know-how and skill-set developed during the course in a “Business Case Workshop” led by expert entrepreneurial trainer Jeff Skinner. They will also get to hear first-hand experiences from four life-science entrepreneurs, one from each site.

FREE REGISTRATION

by 6 March 2023 @ [this link](#)



Enablecares receives funding from the EU's H2020 research & innovation programme under grant agreement No. 101006361. For more information, visit www.enablecares.eu

Jeff Skinner, Teaching Fellow of Strategy and Entrepreneurship at London Business School

Jeff Skinner is the former Director of the Institute of Entrepreneurship and Private Capital at London Business School. As a 'classically trained' researcher (a PhD in thin-film photonics) who later studied for an MBA, his passion has always been to bring together science & business minds & thinking to stimulate the creation of new ventures based on sound science and entrepreneurial ambition. Prior to joining the School, Jeff was commercial director at UCL, where he built its Tech Transfer division – including the creation of two seed-funds and new units to stimulate consultancy, industry engagement and spin-out creation. Working alongside senior academics, he co-founded more than 30 tech-based spin outs that collectively raised >£30 million in 1st round capital. He also introduced management education for engineers & creating the 1st management programmes & degrees for engineers at UCL.. He is the past president of the UK & European Tech Transfer Associations (PraxisAuril and ASTP).



Valerie Vanhooreen, PhD, Chief Executive Officer at Ona Therapeutics

Valerie Vanhooreen co-founded ONA Therapeutics, where she serves as the CEO. She has held previous positions as the R&D Director at ProteoDesign (a spin-off from Princeton University, developing biologics within the immuno-oncology space) & Ablynx (acquired by Sanofi), a biopharmaceutical company engaged in the development of Nanobodies® (proprietary therapeutic proteins). At Ablynx, she led drug development projects from early stage discovery till clinical trials in collaboration with big pharma (Merck, Abbvie etc.). Valerie is a Doctor in Science by the University of Ghent, Belgium & carried out postdoctoral studies at the VIB-Ghent University. She has extensive expertise in immuno-oncology, inflammation & aging research & has published widely in these fields.



Elisa Gambini, PhD, Chief Technology & Operating Officer at Oloker Therapeutics

Elisa Gambini has a 17-year experience in cellular, molecular biology and preclinical models of stem cell therapy and experience in GMP translation of cell products. An expert stem cell scientist of IMPD for Phase I-II cell therapy authorization, Dr. Gambini holds a PhD in Translational and Molecular Medicine and she spent several years in doing research at Centro Cardiologico Monzino (part of IEO group). She is also the co-inventor/co-owner of the patent assigned to the start-up Oloker Therapeutics



Thomas van den Heuvel, PhD, CEO at Ardim & postdoctoral researcher at Radboudumc

Within his work, Thomas combines point-of-care ultrasound with artificial intelligence. Thomas studied Biomedical Engineering at Eindhoven University of Technology. In 2015 he started his PhD project at the Radboudumc. Within this project, he developed the BabyChecker, which enables midwives in rural areas to perform a prenatal ultrasound within two hours of training. The BabyChecker is currently implemented in several resource-limited countries by Delft Imaging. In his current project, Thomas works on automated detection of developmental dysplasia of the hip at the point-of-care. In 2021 he founded Ardim to bring this research to practice.



Prof. Pier Giorgio Mastroberardino, PhD, MBA, PI at IFOM & Erasmus Medical Center

Pier received his PhD from the University of Rome "Tor Vergata". At present, Pier Giorgio continues investigating the molecular mechanisms connecting metabolic alterations and genome quality control in the healthy and diseased brain. Pier Giorgio holds a Global Executive Master degree in Business Administration (MBA) from the Rotterdam School of Management (RSM). He is currently setting up a new joint Master program between the Erasmus Medical Center and RSM focused on Medical Business and Innovation, which intends to educate a new class of professionals with academic background to operate in the business sector. Thanks to the MBA degree, Pier Giorgio is also actively engaged in interactions with the private sector and valorization of scientific discoveries.

